Gufic Biosciences Approves Q3 FY26 Unaudited Results, Invests in Selvax
Gufic Biosciences approved Q3 FY26 unaudited financial results. The company will invest up to USD 50,000 in Selvax Pty Ltd. for 3,78,350 shares at AUD 0.20 each. This strategic move diversifies Gufic into biotechnology for cancer treatments. The acquisition is expected within 4 months.
The investment in Selvax is a strategic diversification into a new sector, which could have significant long-term benefits but is a relatively small financial commitment in the short term.
The company reported its quarterly results and announced a strategic investment in a biotechnology firm focused on cancer treatment, indicating growth and diversification efforts.
Gufic Biosciences Limited announced the outcome of its Board of Directors meeting held on February 13, 2026. The Board approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2025. The company also approved a further investment in Selvax Pty Ltd., an Australian biotechnology company. The investment involves subscribing to 3,78,350 Ordinary shares at AUD 20 cents per share, for a total consideration not exceeding USD 50,000. Selvax is engaged in developing a novel immunology-based treatment for large solid tumors. This strategic arrangement aims to diversify Gufic Biosciences into the healthcare and biotechnology sector, focusing on oncology treatments for humans and animals. The acquisition is expected to be completed within four months. The Board meeting commenced at 06:30 p.m. and concluded at 08:00 p.m. The financial results indicate revenue from operations for the quarter ended December 31, 2025, stood at ₹23,109.36 lakhs on a standalone basis and ₹23,140.99 lakhs on a consolidated basis. For the nine-month period ended December 31, 2025, revenue from operations was ₹68,842.31 lakhs standalone and ₹69,218.69 lakhs consolidated.
Selvax Pty Ltd., incorporated on August 14, 1987, is a biotechnology company focused on developing treatments for solid tumors. Its technology aims to provide novel cancer treatments for animals and humans, potentially overcoming drug resistance and targeting metastatic cancer. The total issued share capital of Selvax as of June 30, 2025, was AUD 52,85,176. The company's turnover for the financial year ended June 30, 2025, was AUD 356,972, AUD 248,817 for FY24, and AUD 220,435.25 for FY23. This investment does not fall within related party transactions, and the promoter group has no interest in Selvax. The acquisition is considered a strategic move for value creation and diversification.
What to do with a filing like this
Gufic Biosciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gufic Biosciences Limited. Read the original for the full detail.